International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

Jens Hillengass, Saad Usmani, S. Vincent Rajkumar, Brian G.M. Durie, María Victoria Mateos, Sagar Lonial, Cristina Joao, Kenneth C. Anderson, Ramón García-Sanz, Eloísa Riva Serra, Juan Du, Niels van de Donk, Jesús G. Berdeja, Evangelos Terpos, Elena Zamagni, Robert A. Kyle, Jesús San Miguel, Hartmut Goldschmidt, Sergio Giralt, Shaji Kumar & 15 others Noopur Raje, Heinz Ludwig, Enrique Ocio, Rik Schots, Hermann Einsele, Fredrik Schjesvold, Wen Ming Chen, Niels Abildgaard, Brea C. Lipe, Dominik Dytfeld, Baldeep Wirk, Matthew Drake, Michele Cavo, Juan José Lahuerta, Suzanne Lentzsch

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.

Original languageEnglish (US)
Pages (from-to)e302-e312
JournalThe Lancet Oncology
Volume20
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Plasma Cells
Multiple Myeloma
Therapeutics
Bone Marrow
Bone and Bones
Bone Diseases
Residual Neoplasm
Disease Management
Clinical Trials
Guidelines
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M. V., Lonial, S., ... Lentzsch, S. (2019). International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet Oncology, 20(6), e302-e312. https://doi.org/10.1016/S1470-2045(19)30309-2
Hillengass, Jens ; Usmani, Saad ; Rajkumar, S. Vincent ; Durie, Brian G.M. ; Mateos, María Victoria ; Lonial, Sagar ; Joao, Cristina ; Anderson, Kenneth C. ; García-Sanz, Ramón ; Serra, Eloísa Riva ; Du, Juan ; van de Donk, Niels ; Berdeja, Jesús G. ; Terpos, Evangelos ; Zamagni, Elena ; Kyle, Robert A. ; San Miguel, Jesús ; Goldschmidt, Hartmut ; Giralt, Sergio ; Kumar, Shaji ; Raje, Noopur ; Ludwig, Heinz ; Ocio, Enrique ; Schots, Rik ; Einsele, Hermann ; Schjesvold, Fredrik ; Chen, Wen Ming ; Abildgaard, Niels ; Lipe, Brea C. ; Dytfeld, Dominik ; Wirk, Baldeep ; Drake, Matthew ; Cavo, Michele ; Lahuerta, Juan José ; Lentzsch, Suzanne. / International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. In: The Lancet Oncology. 2019 ; Vol. 20, No. 6. pp. e302-e312.
@article{d1fbe96f8a2b40438c0521f8ca8eb4b7,
title = "International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders",
abstract = "Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.",
author = "Jens Hillengass and Saad Usmani and Rajkumar, {S. Vincent} and Durie, {Brian G.M.} and Mateos, {Mar{\'i}a Victoria} and Sagar Lonial and Cristina Joao and Anderson, {Kenneth C.} and Ram{\'o}n Garc{\'i}a-Sanz and Serra, {Elo{\'i}sa Riva} and Juan Du and {van de Donk}, Niels and Berdeja, {Jes{\'u}s G.} and Evangelos Terpos and Elena Zamagni and Kyle, {Robert A.} and {San Miguel}, Jes{\'u}s and Hartmut Goldschmidt and Sergio Giralt and Shaji Kumar and Noopur Raje and Heinz Ludwig and Enrique Ocio and Rik Schots and Hermann Einsele and Fredrik Schjesvold and Chen, {Wen Ming} and Niels Abildgaard and Lipe, {Brea C.} and Dominik Dytfeld and Baldeep Wirk and Matthew Drake and Michele Cavo and Lahuerta, {Juan Jos{\'e}} and Suzanne Lentzsch",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/S1470-2045(19)30309-2",
language = "English (US)",
volume = "20",
pages = "e302--e312",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "6",

}

Hillengass, J, Usmani, S, Rajkumar, SV, Durie, BGM, Mateos, MV, Lonial, S, Joao, C, Anderson, KC, García-Sanz, R, Serra, ER, Du, J, van de Donk, N, Berdeja, JG, Terpos, E, Zamagni, E, Kyle, RA, San Miguel, J, Goldschmidt, H, Giralt, S, Kumar, S, Raje, N, Ludwig, H, Ocio, E, Schots, R, Einsele, H, Schjesvold, F, Chen, WM, Abildgaard, N, Lipe, BC, Dytfeld, D, Wirk, B, Drake, M, Cavo, M, Lahuerta, JJ & Lentzsch, S 2019, 'International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders', The Lancet Oncology, vol. 20, no. 6, pp. e302-e312. https://doi.org/10.1016/S1470-2045(19)30309-2

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. / Hillengass, Jens; Usmani, Saad; Rajkumar, S. Vincent; Durie, Brian G.M.; Mateos, María Victoria; Lonial, Sagar; Joao, Cristina; Anderson, Kenneth C.; García-Sanz, Ramón; Serra, Eloísa Riva; Du, Juan; van de Donk, Niels; Berdeja, Jesús G.; Terpos, Evangelos; Zamagni, Elena; Kyle, Robert A.; San Miguel, Jesús; Goldschmidt, Hartmut; Giralt, Sergio; Kumar, Shaji; Raje, Noopur; Ludwig, Heinz; Ocio, Enrique; Schots, Rik; Einsele, Hermann; Schjesvold, Fredrik; Chen, Wen Ming; Abildgaard, Niels; Lipe, Brea C.; Dytfeld, Dominik; Wirk, Baldeep; Drake, Matthew; Cavo, Michele; Lahuerta, Juan José; Lentzsch, Suzanne.

In: The Lancet Oncology, Vol. 20, No. 6, 01.06.2019, p. e302-e312.

Research output: Contribution to journalReview article

TY - JOUR

T1 - International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

AU - Hillengass, Jens

AU - Usmani, Saad

AU - Rajkumar, S. Vincent

AU - Durie, Brian G.M.

AU - Mateos, María Victoria

AU - Lonial, Sagar

AU - Joao, Cristina

AU - Anderson, Kenneth C.

AU - García-Sanz, Ramón

AU - Serra, Eloísa Riva

AU - Du, Juan

AU - van de Donk, Niels

AU - Berdeja, Jesús G.

AU - Terpos, Evangelos

AU - Zamagni, Elena

AU - Kyle, Robert A.

AU - San Miguel, Jesús

AU - Goldschmidt, Hartmut

AU - Giralt, Sergio

AU - Kumar, Shaji

AU - Raje, Noopur

AU - Ludwig, Heinz

AU - Ocio, Enrique

AU - Schots, Rik

AU - Einsele, Hermann

AU - Schjesvold, Fredrik

AU - Chen, Wen Ming

AU - Abildgaard, Niels

AU - Lipe, Brea C.

AU - Dytfeld, Dominik

AU - Wirk, Baldeep

AU - Drake, Matthew

AU - Cavo, Michele

AU - Lahuerta, Juan José

AU - Lentzsch, Suzanne

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.

AB - Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=85066247461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066247461&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30309-2

DO - 10.1016/S1470-2045(19)30309-2

M3 - Review article

VL - 20

SP - e302-e312

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 6

ER -